Home > Dermatology > EADV 2020 > JAK Inhibitors – A Fascinating Novel Drug Class > JAK inhibitors in AA: re-establishing the immune privilege of hair follicles

JAK inhibitors in AA: re-establishing the immune privilege of hair follicles

Presented By
Prof. Taisuke Ito, Hamamatsu University School of Medicine, Japan
Conference
EADV 2020
Janus kinase (JAK) inhibitors are a promising novel treatment option for patients with moderate-to-severe alopecia areata (AA). They seem able to address the immunologic changes noticed in this disease. AA is a poorly treatable autoimmune disease that affects women, men, and children of all ages. This chronic, relapsing, inflammatory disorder is characterised by non-scarring hair loss on the scalp and/or body and has a remarkable negative impact on quality of life. Prof. Taisuke Ito (Hamamatsu University School of Medicine, Japan) explained that hair follicles of healthy subjects have an immune privilege, and that loss of this immune privilege leads to the disease [1]. Certain triggers can lead to activation of NKG2D-expressing CD8+ cytotoxic T lymphocytes, which are necessary for induction of disease. They lead to a type 1 inflammation with upregulation of interleukin (IL)-15 and interferon (IFN)Îł in the outer root sheath of th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on